Greenland Mines Ltd. (NASDAQ: GRML) has released a shareholder letter from President Dr. Bo Møller Stensgaard, detailing significant progress since its rebranding in March. The letter highlights the closing of the Sarfartoq Neodymium-Praseodymium Rare Earths Project acquisition on Sept. 1 and ongoing development at the Skaergaard palladium-gold-platinum project. These moves are part of the company's broader North Atlantic Critical Metals Corridor strategy, aimed at linking Greenland's mineral resources with allied downstream markets.
At the Sarfartoq project, an independent Initial Assessment reported a high-case pre-tax net present value (NPV) of approximately $2.05 billion and an internal rate of return (IRR) of 118.6%, including Indicated and Inferred Mineral Resources. The updated resource estimate shows 6.9 million tonnes of Indicated resources at 1.60% total rare earth oxides (TREO) and 5.3 million tonnes of Inferred resources at 0.96% TREO. Notably, Neo Performance Materials holds a strategic stake in Greenland Mines and has offtake rights for up to 60% of future Sarfartoq production, underscoring the project's commercial viability.
At the Skaergaard project, the July 2026 S-K 1300 Technical Report Summary indicates a 36% increase in Indicated palladium-equivalent (PdEq) grade and a 31% increase in contained Indicated PdEq ounces compared to the 2022 estimate. A comprehensive 2026 field program is underway, encompassing drilling, bulk sampling, geotechnical work, environmental baseline studies, and surveys. Bulk material from Skaergaard is being sent to GTK Mintec in Finland for metallurgical and processing flowsheet testing, which will inform future development decisions.
Looking ahead, Greenland Mines has outlined remaining 2026 milestones, including advancing Sarfartoq toward targeted infill drilling and a Pre-Feasibility Study, and moving Skaergaard toward an Initial Assessment that evaluates a potential mining scenario. These efforts are integral to the company's strategy of building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities.
Greenland Mines operates two divisions: Mining, focused on the exploration and development of the Skaergaard and Sarfartoq projects, and Biotech, which includes Klotho's KLTO-202 primary indication for ALS. The company's vision is to create a North Atlantic Critical Metals Corridor that links Greenland's resources with allied downstream jurisdictions and industrial infrastructure, positioning it as a key player in the critical minerals supply chain.
